Genomic/Proteomic PTB Network: UAB Clinical Core Center

基因组/蛋白质组 PTB 网络：UAB 临床核心中心

• 批准号: 7767765
• 负责人: Joseph Ramon Biggio
• 金额: $ 18.3万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2013-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7767765
• 关键词: Adherence; Area; Clinical; Clinical Research; Clinical Trials Design; Functional disorder; Funding; Genomics; Institution; Intervention; Leadership; Modeling; Morbidity - disease rate; National Institute of Child Health and Human Development; Patients; Performance; Perinatal; Positioning Attribute; Premature Birth; Prevention; Productivity; Proteomics; Protocols documentation; Publications; Ramp; Research; Research Design; Research Infrastructure; Research Personnel; Role; Testing; Women' s Health; base; data acquisition; effective intervention; fetal medicine; improved; member; mortality; prevent; prospective; protocol development; randomized trial; research facility; success

Preterm birth remains the leading cause of perinatal morbidity and mortality, the rate of preterm birth continues to increase, and effective interventions to prevent preterm birth remain illusive. Investigators in the Center for Research in Women's Health at our institution have provided strong clinical research leadership in this area for 25 years. We have successfully acquired millions of dollars in federal funding to conduct clinical studies designed to improve our understanding of the pathophysiology of preterm birth as well as to test many potential interventions in prospective randomized trials. The productivity of our group has resulted in hundreds of publications in the area of preterm birth and its prevention. Our excellence in performing high- quality well-designed clinical trials is widely known. Germane to this application is our particular strength and success in performing multi-center trials and providing a leadership role in research networks including the NICHD Maternal-Fetal Medicine Units Network in which we have been a participating institution for nearly 15 years. Indeed, UAB was ranked first in overall performance among the 14 centers in this Network in the most recent objective ranking of member institutions. Thus, we believe that we are particularly well- positioned, not only to effectively participate, but also to provide leadership as a Clinical Core Center in the proposed Genomic and Proteomic Network. In this application, we will describe in detail our extremely successful clinical research facilities and infrastructure. We will also emphasize our well-documented strengths including patient accrual and retention, high-quality data acquisition and entry, rapid ramp-up to initiate new trials, protocol adherence, analysis and publication productivity, and collaborative success in protocol development and implementation in the NICHD MFMU Network which appears to be a model upon which the proposed new network is based. We believe that our enthusiasm and commitment to this project will be evident and we believe that our qualifications will be very competative for consideration.

早产仍然是围产期发病率和死亡率的主要原因，早产率 继续增加，有效的干预措施以防止早产。调查人员 我们机构的妇女健康研究中心已在 这个区域25年。我们已经成功获得了数百万美元的联邦资金来进行临床 旨在提高我们对早产的病理生理学以及测试的研究 前瞻性随机试验中的许多潜在干预措施。我们小组的生产力已导致 早产及其预防领域的数百个出版物。我们表现​​高的卓越 质量精心设计的临床试验众所周知。该应用程序是我们的特殊优势， 成功地执行多中心试验并在研究网络中发挥领导作用 NICHD孕妇医学单元网络，我们已经成为参与机构近15个 年。确实，UAB在该网络中的14个中心中排名第一 成员机构的最新目标排名。因此，我们相信我们特别是 定位，不仅可以有效地参与，而且还可以作为临床核心中心提供领导 提出的基因组和蛋白质组学网络。在此应用程序中，我们将详细描述我们的极端 成功的临床研究设施和基础设施。我们还将强调我们有据可查的 包括患者应计和保留率在内的优势，高质量的数据获取和进入，快速升级到 启动新的试验，协议遵守，分析和出版生产力，并在 NICHD MFMU网络中的协议开发和实施，该网络似乎是一个模型 拟议的新网络是基于的。我们相信我们对这个项目的热情和承诺 将是显而易见的，我们认为我们的资格将非常有竞争力的考虑。